Pegylated interferon beta-1a (Plegridy) Italian real-world experience: a Delphi analysis of injection-site reaction and flu-like symptom management
ConclusionsPatient education and counseling play a key role in promoting adherence to treatment especially in the first months also in patients switching from nonpegylated IFNs to peginterferon beta-1a. (Source: Neurological Sciences)
Source: Neurological Sciences - January 13, 2021 Category: Neurology Source Type: research
Comparison of Therapies in MS Patients After the First Demyelinating Event in Real Clinical Practice in the Czech Republic: Data From the National Registry ReMuS
Conclusion: Small differences were found among GA, IFNβ and teriflunomide therapies, with no significant impact on the final outcome after 2 years. Therefore, in clinical practice, we recommend choosing the drug based on individual potential risk from long-term therapy and on patient preferences and clinical characteristics. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - January 12, 2021 Category: Neurology Source Type: research
Antibody-Based Targeting of Interferon-Beta-1a Mutein in HER2-Positive Cancer Enhances Antitumor Effects Through Immune Responses and Direct Cell Killing
This study aimed to construct recombinant IFN-β-1a mutein immunocytokines that comprise a human epidermal growth factor receptor 2 (HER2)-targeting antibody and IFN-β muteins with an additional glycosylation, which can overcome the limitation of the cytokine itself. Hence, the molecular design aims to 1) enhance productivity and biophysical properties by adding secondary glycosylation in IFN-β, 2) increase the therapeutic index of IFN-β therapy by preferential retention at the tumor by possessing high affinity for HER2-expressing cancer cells, and 3) improve the pharmacokinetics and, thus, the convenience of IFN-β adm...
Source: Frontiers in Pharmacology - January 8, 2021 Category: Drugs & Pharmacology Source Type: research
SARS-CoV-2, multiple sclerosis, and focal deficit in a postpartum woman: A case report.
This report raises several problems. The focal deficit could be a real relapse or a pseudo-relapse due to SARS-CoV-2 and postpartum patient vulnerability. The treatment options in this particular case raise many challenges. The absence of antibodies after a SARS-CoV-2 infection raises a big question over the acquired immunity, the increased risk of reinfection, and the subsequent evolution of MS. The standard of care for a woman with MS and COVID-19 infection during the postpartum period must be explored and more precise recommendations must be established in the future.
PMID: 33363603 [PubMed] (Source: Experimenta...
Source: Experimental and Therapeutic Medicine - December 29, 2020 Category: General Medicine Tags: Exp Ther Med Source Type: research
Nebulised interferon beta-1a for patients with COVID-19
Publication date: Available online 12 November 2020Source: The Lancet Respiratory MedicineAuthor(s): Nathan Peiffer-Smadja, Yazdan Yazdanpanah (Source: The Lancet Respiratory Medicine)
Source: The Lancet Respiratory Medicine - November 13, 2020 Category: Respiratory Medicine Source Type: research
Safety and efficacy of inhaled nebulised interferon beta-1a (SNG001) for treatment of SARS-CoV-2 infection: a randomised, double-blind, placebo-controlled, phase 2 trial
Publication date: Available online 12 November 2020Source: The Lancet Respiratory MedicineAuthor(s): Phillip D Monk, Richard J Marsden, Victoria J Tear, Jody Brookes, Toby N Batten, Marcin Mankowski, Felicity J Gabbay, Donna E Davies, Stephen T Holgate, Ling-Pei Ho, Tristan Clark, Ratko Djukanovic, Tom M A Wilkinson, Michael G Crooks, Davinder PS Dosanjh, Salman Siddiqui, Najib M Rahman, Jacklyn A Smith, Alexander Horsley, Timothy W Harrison (Source: The Lancet Respiratory Medicine)
Source: The Lancet Respiratory Medicine - November 13, 2020 Category: Respiratory Medicine Source Type: research
Evaluation of the efficacy and safety of favipiravir and interferon compared to lopinavir/ritonavir and interferon in moderately ill patients with COVID-19: a structured summary of a study protocol for a randomized controlled trial
We will evaluate the efficacy and safety of favipiravir and interferon beta-1a compared to lopinavir/ritonavir and interferon beta-1a in patients with confirmed COVID-19, who are moderately ill. (Source: Trials)
Source: Trials - October 27, 2020 Category: General Medicine Authors: Mehdi Hassaniazad, Ali Bazram, Soheil Hassanipour and Mohammad Fathalipour Tags: Letter Source Type: research
Delay from treatment start to full effect of immunotherapies for multiple sclerosis
In conclusion we have developed, and externally validated, a method to objectively quantify the duration of therapeutic lag on relapses and disability progres sion in different therapies in patients more than 3 years from multiple sclerosis onset. Objectively defined periods of expected therapeutic lag allows insights into the evaluation of treatment response in randomized clinical trials and may guide clinical decision-making in patients who experience e arly on-treatment disease activity. This method will subsequently be applied in studies that evaluate the effect of patient and disease characteristics on therapeutic lag. (Source: Brain)
Source: Brain - September 18, 2020 Category: Neurology Source Type: research
Patterning Chronic Active Demyelination in Slowly Expanding/Evolving White Matter MS Lesions [FUNCTIONAL]
CONCLUSIONS:
Patterns of longitudinal change in the normalized magnetization transfer ratio and DTI radial diffusivity in slowly expanding/evolving lesions were consistent with progressive demyelination and tissue loss, as seen in smoldering white matter MS plaques. (Source: American Journal of Neuroradiology)
Source: American Journal of Neuroradiology - September 8, 2020 Category: Radiology Authors: Elliott, C., Arnold, D. L., Chen, H., Ke, C., Zhu, L., Chang, I., Cahir-McFarland, E., Fisher, E., Zhu, B., Gheuens, S., Scaramozza, M., Beynon, V., Franchimont, N., Bradley, D. P., Belachew, S. Tags: FUNCTIONAL Source Type: research
Clinical Parameters to Predict Future Clinical Disease Activity After Treatment Change to Higher-Dose Subcutaneous Interferon Beta-1a From Other Platform Injectables in Patients With Relapsing-Remitting Multiple Sclerosis
Conclusions: Patients with a polysymptomatic index relapse and/or higher number of relapses within 2 years prior to baseline are at high risk of clinical disease activity, despite treatment change to higher-dose interferon beta-1a from other platform injectable therapy.Trial registration: State Institute of Drug Control (SUKL), URL: http://www.sukl.eu/modules/nps/index.php?h=study&a=detail&id=958&lang=2, registration number 1205090000. (Source: Frontiers in Neurology)
Source: Frontiers in Neurology - September 1, 2020 Category: Neurology Source Type: research
Ozanimod (Zeposia) for Multiple Sclerosis
Date: August 24, 2020
Issue #:
1605Summary:
The FDA has approved ozanimod (Zeposia– Celgene),
a sphingosine 1-phosphate (S1P) receptor modulator,
for treatment of adults with relapsing forms of multiple
sclerosis (MS), including clinically isolated syndrome
(initial neurological episode), relapsing-remitting
disease, and active secondary progressive MS
(SPMS). It is the third o ral S1P receptor modulator to
be approved in the US for treatment of relapsing forms
of MS; siponimod(Mayzent) is also indicated for use
in adults, and fingolimod(Gilenya) is approved for use
in patients...
Source: The Medical Letter - July 21, 2020 Category: Drugs & Pharmacology Authors: admin Tags: Alemtuzumab Arzerra Aubagio Avonex Copaxone dimethyl fumarate diroximel Fingolimod Gilenya Glatect Glatiramer acetate Glatopa Interferon beta Lemtrada Mayzent Multiple sclerosis Natalizumab ocrelizumab Ocrevus Ofatumu Source Type: research
Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223
ConclusionsAlemtuzumab efficacy was maintained over 12 years in CAMMS223 patients, with 73% receiving no more than three courses. The safety profile in this cohort was consistent with other alemtuzumab clinical trials. (Source: Journal of Neurology)
Source: Journal of Neurology - June 23, 2020 Category: Neurology Source Type: research
Interferon beta-1a for COVID-19: critical importance of the administration route
(Source: Critical Care)
Source: Critical Care - June 12, 2020 Category: Intensive Care Authors: Juho Jalkanen, Maija Hollm én and Sirpa Jalkanen Tags: Commentary Source Type: research
Interferon Beta-1a Cardiomyopathy in a Patient with Multiple Sclerosis: Case Report
Publication date: Available online 22 May 2020Source: Multiple Sclerosis and Related DisordersAuthor(s): H. Cheraghmakani, H.R. Samaee, M. Ghazaeian (Source: Multiple Sclerosis and Related Disorders)
Source: Multiple Sclerosis and Related Disorders - May 22, 2020 Category: Neurology Source Type: research
Interferons in the Therapy of Severe Coronavirus Infections: A Critical Analysis and Recollection of a Forgotten Therapeutic Regimen with Interferon Beta
Drug Res (Stuttg) DOI: 10.1055/a-1170-4395The pharmacological and immunological properties of interferons, especially those of interferon beta, and the corresponding treatment strategies are described, and the results of studies with different interferons in coronavirus infections are analysed. Furthermore, the data obtained with high-dosed native interferon beta in life-threatening acute viral diseases as well as the results of clinical pilot studies with high-dosed recombinant interferon beta-1a are provided because they serve as the rationale for the proposed therapeutic regimen to be applied in acute viral infections. ...
Source: Drug Research - May 21, 2020 Category: Drugs & Pharmacology Authors: Brzoska, Josef von Eick, Harald H ündgen, Manfred Tags: Opinion Paper Source Type: research
